ILMN - Illumina, Inc.

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
210,56
+3,25 (+1,57%)
Börsenschluss: 04:00PM EDT
208,50 -2,06 (-0,98%)
Nachbörse: 06:23PM EDT
Das Aktien-Chart wird von Ihrem aktuellen Browser nicht unterstützt
Kurs Vortag207,31
Öffnen208,14
Gebot198,11 x 1300
Briefkurs210,50 x 800
Tagesspanne206,91 - 213,11
52-Wochen-Spanne173,45 - 248,87
Volumen1.109.953
Durchschn. Volumen1.290.390
Marktkap.33,29B
Beta (5 J., monatlich)1,18
Kurs-Gewinn-Verhältnis (roll. Hochrechn.)N/A
EPS (roll. Hochrechn.)-30,08
Gewinndatum09. Aug. 2023 - 14. Aug. 2023
Erwartete Dividende & RenditeN/A (N/A)
Ex-DividendendatumN/A
1-Jahres-Kursziel238,92
  • Bloomberg

    Etwas wie Archegos: Ackman sieht Milliardär Icahn angezählt

    (Bloomberg) -- Bill Ackman sieht die Art und Weise, wie Milliardär Carl Icahn seinen börsennotierten Konzern führt, durch den Leerverkäufer Hindenburg Research angezählt. Bei der Aktie der Icahn Enterprises LP, deren Kurs bereits auf den niedrigsten Stand seit 2009 gefallen ist, besteht laut dem ebenfalls milliardenschweren Hedgefondsmanager noch Spielraum nach unten. Weitere Artikel von Bloomberg auf Deutsch:Inflation schwächt sich ab, EZB-Straffung kommt Ende näherEZB-Vize Guindos ruft Banken

  • PR Newswire

    Illumina liefert erstes NovaSeq X Plus-Sequenziergerät an das Broad Institute

    Illumina Inc. (NASDAQ: ILMN), ein weltweit führender Anbieter von DNA-Sequenzierungs- und Array-Technologien, gab heute bekannt, dass sein erstes NovaSeq X Plus-System kürzlich an das Broad Institute geliefert wurde. Alex Aravanis, PhD, Chief Technology Officer von Illumina, gab dies heute in einer Präsentation auf der Konferenz „Advances in Genome Biology and Technology" (AGBT) in Hollywood, Florida, bekannt. Aravanis kündigte auch die mit Spannung erwarteten Aktualisierungen der Innovations-Ro

  • ACCESSWIRE

    Greenwood Genetic Center: Answering the Unanswered

    Before next-generation sequencing (NGS) came along, children and families with rare and undiagnosed genetic diseases often faced years-long diagnostic odysseys.

  • ACCESSWIRE

    New Virtual Lab for Students Opens Access to Next-Generation Sequencing

    While visiting her grandparents in Florida, 17-year-old Kate frequented a pond near their house and spent time observing the various species of fish living there.

  • ACCESSWIRE

    RNA Sequencing Critical to Identifying Key Fusions for Oncology Patients

    NORTHAMPTON, MA / ACCESSWIRE / November 8, 2022 / Illumina: At the Phoenix Convention Center in Arizona, representatives from Illumina, a global leader in DNA sequencing and array-based technologies, joined approximately 2000 molecular diagnostic ...

  • ACCESSWIRE

    Rarebase Is on the Hunt for Therapeutic Opportunities

    San Francisco Bay Area residents Jainu and Shruti Jogani had their newborn daughter, Reyna, at home for nearly three weeks when they noticed her exhibiting seizure-like symptoms-episodes so quick they weren't able to capture them on video. Standard blood work, MRI scans, and EKGs all came back normal, except for a gene panel for epilepsy.

  • ACCESSWIRE

    Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

    Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, announced a new research test for genitourinary pathogen and antimicrobial resistance (AMR) identification.

  • ACCESSWIRE

    IGB Gene Drive Aims To Broaden Science Accessibility

    Advances in genomic studies have now permeated all aspects of our lives from agriculture to health and wellness. It is therefore becoming increasingly important to help the community understand these innovations so that they can navigate the increasingly complex realm of genomics. To this end, the outreach team at the Carl R.

  • ACCESSWIRE

    Empowering the Disability Community at Illumina

    "The Spoon Theory," a personal story by patient advocate Christine Miserandino, imagines "spoons" as a measurement of one's daily energy to illustrate what it's like to ration that energy.

  • ACCESSWIRE

    Can Genomics Stop the World's Leading Cause of Death?

    For decades, cardiovascular disease has remained the number-one cause of death. In 2019 alone, nearly 18 million people around the world died from cardiovascular diseases (CVDs), which include disorders such as coronary heart disease, heart failure, and cerebrovascular disease.

  • ACCESSWIRE

    Francis deSouza Recognized as 3BL Media's Responsible CEO of the Year for Innovation and ESG Integration

    Illumina CEO, Francis deSouza received the award for 3BL Media's 2022 Responsible CEO of the Year: Innovation and ESG Integration. 3BL Media presents Responsible CEO of the Year awards to corporate executives who embody leadership in delivering on their environmental, social, and governance (ESG) commitments.

  • ACCESSWIRE

    Illumina To Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022

    Illumina, Inc. (NASDAQ:ILMN) announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:30 am Pacific Time (12:30 pm Eastern Time), Friday, October 28, 2022.

  • ACCESSWIRE

    Australia Begins a Big Push To Sequence Underserved Populations

    Australia's Centre for Population Genomics (CPG), a collaboration between the Garvan Institute of Medical Research and the Murdoch Children's Research Institute, has launched a new initiative to engage diverse communities in genomic research.

  • Business Wire

    Illumina Ventures gibt Erweiterung seines Europa-Teams bekannt

    SAN FRANCISCO, August 04, 2022--Illumina Ventures, eine unabhängig verwaltete, auf das Gesundheitswesen ausgerichtete Risikofirma in einer strategischen Partnerschaft mit Illumina (NASDAQ: ILMN), teilte heute die Aufnahme von vier neuen Mitgliedern in ihr europäisches Team mit. Arnaud Autret, PhD, MSc, wird Principal und Head of European Operations, William Byrne, PhD, wird Associate – Europe, und Ronan Byrne und Ivan Coulter, PhD, BSc, werden als Venture Advisors – Europe tätig sein.